3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
4
Sarcoma
1
Classical hematology
1
Conditions
Stomach Neoplasms
1
Sarcoma
1
Pancreatic Neoplasms
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Lymphoma
1
Gliosarcoma
1
Glioblastoma
1
Gastrointestinal Stromal Tumors
1
Gallbladder Neoplasms
1
Fractures, Spontaneous
1
Femoral Fractures
1
Esophageal Neoplasms
1
Duodenal Neoplasms
1
Cholangiocarcinoma
1
Central Nervous System Neoplasms
1
Carcinoma, Hepatocellular
1
Bone Neoplasms
1
Biliary Tract Neoplasms
1
Interventions
Gemcitabine
9
pembrolizumab
7
Irinotecan
5
Docetaxel
4
Cisplatin
4
Carboplatin
4
Capecitabine
4
Albumin-Bound Paclitaxel
4
Paclitaxel
3
Oxaliplatin
3
Leucovorin
3
Cyclophosphamide
3
Cetuximab
3
130-nm albumin-bound paclitaxel
3
pazopanib
2
palbociclib
2
liposomal doxorubicin
2
entrectinib
2
alectinib
2
Vinorelbine
2
Trastuzumab
2
Taxes
2
Radiosurgery
2
Oncolytic Virotherapy
2
Observation
2
Ipilimumab
2
Fluorouracil
2
Fluorodeoxyglucose F18
2
Filgrastim
2
Erlotinib Hydrochloride
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pancreatic Neoplasms
×
Dalteparin
×
Sarcoma
×
Clear all
NCT03139487
2020-01-06
PRIORITY
Asan Medical Center
Phase 2
Unknown
176 enrolled